A phase II Clinical Trial on the use of ARA 290 for the treatment of Diabetic Macular Oedema

Trial Profile

A phase II Clinical Trial on the use of ARA 290 for the treatment of Diabetic Macular Oedema

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Cibinetide (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 May 2016 Status changed from not yet recruiting to recruiting as per Ariam Pharmaceuticals media release.
    • 10 May 2016 According to Ariam Pharmaceuticals media release, company has enrolled the first patient.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top